In 2023, the import value of insulin to the US stood at a certain level and is projected to decline steadily from 2024 to 2028, starting at $70.993 million in 2024 and decreasing to $51.794 million by 2028. These forecasted values reflect annual decreases as follows: a 6.97% drop from 2024 to 2025, a 7.33% decrease from 2025 to 2026, a 7.76% reduction from 2026 to 2027, and an 8.24% fall from 2027 to 2028. The overall compound annual growth rate (CAGR) over this five-year period is projected to be negative.
Future trends to watch for include:
- The impact of domestic production advancements.
- Potential policy changes affecting import tariffs or healthcare regulations.
- Technological innovations in insulin delivery and production that could influence market dynamics.
- Global market shifts and competitive pressures from other countries increasing their market share.
